Home›Stock Screener›Aarti Drugs›Quarterly Results

Aarti Drugs Quarterly Results

Latest Quarter Net Profit
₹55 Cr
QMar 2026
Quarterly Results

Aarti Drugs quarterly results. In Mar 2026, Aarti Drugs (AARTIDRUGS) reported revenue ₹721 Cr and net profit ₹55 Cr — revenue +6.2% YoY. For annual financials, live price and key ratios, visit Aarti Drugs stock price NSE.

AARTIDRUGS Quarterly Results — Revenue, Profit & EPS Highlights

Aarti Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Aarti Drugs marketcap in USD to track the company's total market size over time.

  • Revenue of ₹721 Cr in Mar 2026 (+2.4% vs Jun 2026, +6.2% vs Mar 2025)
  • Net Profit of ₹55 Cr in Mar 2026 (+10.0% vs Jun 2026, -12.7% vs Mar 2025)
  • EBITDA of ₹97 Cr in Mar 2026 (+0.0% vs Jun 2026)
  • Operating Margin of 13.0% in Mar 2026 (-1.0pp vs Jun 2026)
  • Earnings Per Share of ₹6.05 in Mar 2026 (+10.2% vs Jun 2026)

Aarti Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS

AARTIDRUGS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 721 704 653 679 591 2.4% 6.2%
Net Profit (₹ Cr) 55 50 45 63 54 - -
EBITDA (₹ Cr) 97 97 84 95 74 - -
EPS (₹) 6.05 5.49 4.95 6.88 5.91 - -
Operating Margin (%) 13.0% 14.0% 13.0% 14.0% 13.0% - -

AARTIDRUGS Share Price Trend — 1-Year Movement Across Quarterly Results

Aarti Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review Aarti Drugs P/E valuation to evaluate earnings-based valuation against sector peers.

Profitability Ratios

Profit Margin 7.6%
EBITDA Margin 13.5%
Operating Margin 13.0%
ROE (Annual) 14.2%

Balance Sheet Highlights

Total Assets ₹2,815 Cr
Total Equity ₹1,549 Cr
Current Assets ₹1,468 Cr
Current Liabilities ₹344 Cr

Cash Flow Analysis

Operating Cash Flow ₹254 Cr
Investing Cash Flow ₹-173 Cr
Financing Cash Flow ₹-77 Cr
Net Cash Flow ₹3 Cr

Current Market Data

Current Price ₹415.00
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 679
Sept 2025 653
Jun 2026 704
Mar 2026 721

Net Profit Trend (₹ Cr)

Mar 2025 63
Sept 2025 45
Jun 2026 50
Mar 2026 55

Operating Margin Trend (%)

Mar 2025 14.0%
Sept 2025 13.0%
Jun 2026 14.0%
Mar 2026 13.0%

AARTIDRUGS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Aarti Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹253,522.49 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores